Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Matuzumab plus irinotecan in EGFR-expressing metastatic colorectal cancer after irinotecan failure
2005-001362-14Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- May 2005
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of matuzumab and irinotecan in colorectal cancer (CRC), sponsored by Merck KGaA. Primary endpoint: Response rate. Started May 2005; status: completed.
02
Drugs
matuzumabirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2005-001362-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001362-14.